Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

Corcept Therapeutics' Chief Development Officer William Guyer sold 20,000 shares for $1.9 million on July 7, 2026, liquidating 83% of his direct holdings under a Rule 10b5-1 plan established in November 2024. Guyer retains 130,000 stock options following the transaction.

The insider sale follows recent positive catalysts. Corcept secured FDA approval for Lifyorli, a cortisol-blocking ovarian cancer drug, ahead of its scheduled timeline. The company raised full-year revenue guidance to a range of $950 million to $1.05 billion on the strength of its expanding portfolio.

The timing creates tension for investors. Q1 results showed a $31.8 million loss driven by heavy commercial launch spending for new therapies. The combination of accelerated approval, upgraded revenue targets, and simultaneous executive selling presents mixed signals on near-term sentiment versus long-term positioning.

Guyer's trade was pre-scheduled 20 months before execution, standard protocol for corporate insiders, though the 83% reduction in direct holdings stands out in magnitude despite his retained option position.